Last reviewed · How we verify
NCT02352025
S-equol in Women With Triple Negative Breast Cancer
Completed
EARLY_PHASE1
Last updated 22 July 2020
What this trial tests
EARLY_PHASE1 trial testing S-equol in Breast Cancer in 39 participants. Completed in 30 June 2020.
Timeline
15 April 2015
Primary endpoint
10 April 2019
10 April 2019
30 June 2020
Quick facts
| Lead sponsor | The University of Texas Health Science Center at San Antonio |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 39 |
| Start date | 15 April 2015 |
| Primary completion | 10 April 2019 |
| Estimated completion | 30 June 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- S-equol — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
The University of Texas Health Science Center at San Antonio
Who can join
18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this study is to determine if S-equol, an ER-beta agonist, is effective in decreasing the proliferation rate of triple negative breast cancer.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent progress in DNA methyltransferase inhibitors as anticancer agents.
Zhang Z, Wang G, Li Y, Lei D, et al · · 2022 · cited 96× · PMID 37077808 · DOI 10.3389/fphar.2022.1072651 -
Estrogen receptor beta signaling in CD8<sup>+</sup> T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch.
Yuan B, Clark CA, Wu B, Yang J, et al · · 2021 · cited 40× · PMID 33462142 · DOI 10.1136/jitc-2020-001932 -
Insights into the Role of Estrogen Receptor β in Triple-Negative Breast Cancer.
Sellitto A, D'Agostino Y, Alexandrova E, Lamberti J, et al · · 2020 · cited 34× · PMID 32516978 · DOI 10.3390/cancers12061477 -
Targeting Breast Cancer Stem Cells Using Naturally Occurring Phytoestrogens.
Nguyen M, Osipo C. · · 2022 · cited 24× · PMID 35743256 · DOI 10.3390/ijms23126813 -
Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Bano A, Stevens JH, Modi PS, Gustafsson JÅ, et al · · 2023 · cited 10× · PMID 36982940 · DOI 10.3390/ijms24065867 -
Flavonoid-Based Combination Therapies and Nano-Formulations: An Emerging Frontier in Breast Cancer Treatment.
Uniyal P, Akhtar A, Rawat R. · · 2025 · cited 2× · PMID 41155601 · DOI 10.3390/ph18101486 -
Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?
Das GM, Oturkar CC, Menon V. · · 2025 · cited 2× · PMID 39891710 · DOI 10.1210/endocr/bqaf020
Verify or expand the search:
- PubMed search for NCT02352025
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of S-equol
Trials testing the same drug.
- NCT05741060 — Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers · Phase 2 · active not recruiting
- NCT06128278 — Acute Equol Supplementation and Vascular Function in Women With and Without CKD · Phase 2 · recruiting
- NCT04516304 — A Nutritional Supplement on Vasomotor Symptoms in Women · NA · completed
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other The University of Texas Health Science Center at San Antonio trials
Trials by the same sponsor.
- NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
- NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
- NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02352025 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
- Last refreshed: 22 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02352025.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing